The Hunger Hormone Ghrelin Extended Survival in Mice with Heart Failure
Daily ghrelin injections extended the lifespan of mice with genetic heart failure while improving heart function, reducing scarring, and rebalancing the autonomic nervous system.
Quick Facts
What This Study Found
Daily ghrelin injections significantly extended the lifespan of mice with inherited dilated cardiomyopathy (DCM) compared to saline-treated controls over a 30-day treatment period. Beyond survival, ghrelin improved multiple measures of heart function: it reduced left ventricular dilation, increased ejection fraction (the heart's pumping efficiency), decreased the heart-to-body weight ratio, prevented cardiac remodeling and fibrosis, and lowered brain natriuretic peptide (BNP) expression — a key marker of heart failure severity.
The mechanism appears to involve the autonomic nervous system: ghrelin suppressed the excessive sympathetic nerve activity that drives heart failure progression and restored parasympathetic (calming) nerve activity to the heart. This rebalancing of the nervous system may be central to ghrelin's cardioprotective effects.
Key Numbers
Ghrelin 150 μg/kg/day SC · 30-day treatment from age 30 days · significantly prolonged survival · increased LV ejection fraction · reduced LV end-diastolic dimensions · decreased heart-to-body weight ratio · reduced BNP expression · suppressed cardiac sympathetic nerve activity
How They Did This
Mice with inherited dilated cardiomyopathy (caused by a ΔK210 mutation in cardiac troponin T) received daily subcutaneous injections of ghrelin (150 μg/kg) or saline starting at 30 days of age for 30 days. Survival was compared between groups. After treatment, researchers performed echocardiography (heart ultrasound), histological analysis of heart tissue for remodeling and fibrosis, BNP expression measurement, and telemetry recording with heart rate variability analysis to assess autonomic nervous system activity.
Why This Research Matters
Heart failure from dilated cardiomyopathy is a leading cause of death, and current treatments have limited ability to reverse the disease. This is the first study to demonstrate that ghrelin — the hunger hormone — can actually extend survival in a genetic heart failure model, not just improve symptoms. The mechanism involving sympathetic nerve suppression is particularly interesting because overactive sympathetic drive is a well-known accelerator of heart failure that current beta-blocker therapy only partially addresses.
The Bigger Picture
Ghrelin's heart-protective effects have been documented in several studies, but this is among the first to show an actual survival benefit. Heart failure treatment has improved with modern drugs (ACE inhibitors, beta-blockers, SGLT2 inhibitors), but the disease still carries high mortality. If ghrelin or its analogs can extend life by targeting the autonomic nervous system imbalance that drives heart failure progression, they could add a genuinely novel mechanism to the treatment toolkit.
What This Study Doesn't Tell Us
This is a mouse study using a specific genetic model of dilated cardiomyopathy that may not represent all forms of human heart failure. The 30-day treatment window is relatively short. Specific survival percentages and statistical values are not provided in the abstract. The ghrelin dose used may not translate directly to human dosing. Ghrelin's appetite-stimulating effects could complicate its use in heart failure patients. Long-term safety of daily ghrelin administration was not assessed.
Questions This Raises
- ?Would longer-term ghrelin treatment produce even greater survival benefits, or would the effect plateau?
- ?Can ghrelin's cardioprotective effects be separated from its appetite-stimulating properties for clinical use?
- ?Has ghrelin been tested in human heart failure patients, and if so, do the autonomic nervous system effects translate?
Trust & Context
- Key Stat:
- Survival extended First demonstration that ghrelin extends lifespan in a genetic heart failure model, not just improves cardiac function
- Evidence Grade:
- This is a preclinical study in a mouse model of genetic heart failure. While it demonstrates a survival benefit with clear mechanistic data, the 'Preliminary' grade reflects that these findings have not been validated in human heart failure patients.
- Study Age:
- Published in 2014, this study contributed to the growing body of evidence for ghrelin's cardioprotective effects. Subsequent research has continued to explore ghrelin and its analogs in cardiac contexts, though human heart failure trials remain limited.
- Original Title:
- Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy.
- Published In:
- Pharmacology research & perspectives, 2(5), e00064 (2014)
- Authors:
- Du, Cheng-Kun, Zhan, Dong-Yun, Morimoto, Sachio, Akiyama, Tsuyoshi, Schwenke, Daryl O, Hosoda, Hiroshi, Kangawa, Kenji, Shirai, Mikiyasu
- Database ID:
- RPEP-02376
Evidence Hierarchy
Frequently Asked Questions
Why would a hunger hormone help a failing heart?
Ghrelin does much more than make you hungry. It has receptors throughout the cardiovascular system and directly affects the autonomic nervous system that controls heart rate and blood vessel tone. In heart failure, the sympathetic nervous system goes into overdrive — constantly flooding the heart with stress signals that make it work harder and deteriorate faster. Ghrelin appears to calm this overdrive while restoring the parasympathetic 'rest and digest' signals, taking pressure off the failing heart.
Could ghrelin be used to treat human heart failure?
Small human studies have shown that ghrelin infusions can temporarily improve cardiac output and exercise capacity in heart failure patients. However, there are no approved ghrelin-based heart failure treatments. Challenges include ghrelin's short half-life (requiring frequent dosing), its appetite-stimulating effects, and the need for larger clinical trials to prove long-term safety and survival benefits in humans.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02376APA
Du, Cheng-Kun; Zhan, Dong-Yun; Morimoto, Sachio; Akiyama, Tsuyoshi; Schwenke, Daryl O; Hosoda, Hiroshi; Kangawa, Kenji; Shirai, Mikiyasu. (2014). Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy.. Pharmacology research & perspectives, 2(5), e00064. https://doi.org/10.1002/prp2.64
MLA
Du, Cheng-Kun, et al. "Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy.." Pharmacology research & perspectives, 2014. https://doi.org/10.1002/prp2.64
RethinkPeptides
RethinkPeptides Research Database. "Survival benefit of ghrelin in the heart failure due to dila..." RPEP-02376. Retrieved from https://rethinkpeptides.com/research/du-2014-survival-benefit-of-ghrelin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.